Abstract: Leprosy, caused by Mycobacterium leprae (M. leprae), is treated with a multidrug regimen comprising Dapsone, Rifampicin, and Clofazimine. These drugs exhibit bacteriostatic, bactericidal and anti-inflammatory properties, respectively, and control the dissemination of infection in the host. However, the current treatment is not cost-effective, does not favor patient compliance due to its long duration (12 months) and does not protect against the incumbent nerve damage, which is a severe leprosy complication. The chronic infectious peripheral neuropathy associated with the disease is primarily due to the bacterial components infiltrating the Schwann cells that protect neuronal axons, thereby inducing a demyelinating phenotype. There is a need to discover novel/repurposed drugs that can act as short duration and effective alternatives to the existing treatment regimens, preventing nerve damage and consequent disability associated with the disease. Mycobacterium leprae is an obligate pathogen resulting in experimental intractability to cultivate the bacillus in vitro and limiting drug discovery efforts to repositioning screens in mouse footpad models. The dearth of knowledge related to structural proteomics of M. leprae, coupled with emerging antimicrobial resistance to all the three drugs in the multidrug therapy, poses a need for concerted novel drug discovery efforts. A comprehensive understanding of the proteomic landscape of M. leprae is indispensable to unravel druggable targets that are essential for bacterial survival and predilection of human neuronal Schwann cells. Of the 1,614 protein-coding genes in the genome of M. leprae, only 17 protein structures are available in the Protein Data Bank. In this review, we discussed efforts made to model the proteome of M. leprae using a suite of software for protein modeling that has been developed in the Blundell laboratory. Precise template selection by employing sequence-structure homology recognition software, multi-template modeling of the monomeric models and accurate quality assessment are the hallmarks of the modeling process. Tools that map interfaces and enable building of homo-oligomers are discussed in the context of interface stability. Other software is described to determine the druggable proteome by using information related to the chokepoint analysis of the metabolic pathways, gene essentiality, homology to human proteins, functional sites, druggable pockets and fragment hotspot maps.
Introduction: The Challenge of the "Unculturable"
Leprosy remains a significant global health challenge, with roughly 200,000 new cases annually. While a multidrug therapy (MDT) exists, it requires a grueling 12-month regimen, suffers from emerging antibiotic resistance, and fails to prevent the permanent nerve damage that defines the disease's morbidity. The primary hurdle in leprosy research is that Mycobacterium leprae is an obligate pathogen—it cannot be cultured in vitro. This "experimental intractability" means drug testing is largely limited to slow, expensive mouse footpad models.
Furthermore, there is a massive structural "dark matter" problem: while we know the sequences of the 1,614 protein-coding genes in the M. leprae genome, only 17 of those proteins have solved structures in the Protein Data Bank (PDB). Without 3D structures, scientists cannot perform structure-guided drug design to find new treatments that are shorter, more effective, or capable of preventing the peripheral nerve damage caused by the bacteria infiltrating human Schwann cells.
Methodology: The Vivace Pipeline
To bridge this gap, researchers are employing sophisticated "comparative modeling" approaches. Central to this effort is the Vivace pipeline, a multi-task computational workflow that automates template selection, sequence-structure alignment, and 3D model building.
Since M. leprae is a close relative of M. tuberculosis (which has ~1,277 solved structures), the pipeline uses M. tuberculosis proteins as 3D blueprints (templates). Tools like FUGUE and TOCCATA allow for "distant homology recognition," finding structural matches even when genetic sequence identity is low. The authors emphasize building homo-oligomers (complexes of multiple identical protein chains), as many drug targets only function in these multi-unit states.
Strategic Target Prioritization
Identifying a protein's structure is only the first step; researchers must then determine which proteins are the best candidates for drug inhibition. The study advocates for a "chokepoint" strategy, targeting enzymes that are either the sole producer or the sole consumer of a specific metabolite. Inhibiting these is more likely to be lethal to the bacteria.
As shown in Figure 3, the prioritization workflow integrates multiple data streams, including gene essentiality, chokepoint analysis, and a lack of homology to human proteins (to minimize side effects). The pipeline also maps "fragment hotspots" where small chemical fragments are likely to bind, providing a literal map for medicinal chemists to follow.
Predicting Resistance and Future Directions
By mapping mutations onto 3D models using the mCSM suite, researchers can identify "hotspots" where mutations are likely to cause drug resistance. This allows for the design of "resistance-proof" drugs that bind to more conserved regions of the protein. This data is compiled in the HARP (Hansen’s Disease Antimicrobial Resistance Profiles) repository.
While computational models are predictions, they provide a vital roadmap for tackling the "dark proteome" of leprosy. Future work must focus on the structural basis of how M. leprae interacts with human neuronal cells, which is the root cause of the disease's most debilitating symptoms.
Summary updated